Itoh Kuniaki | Contributors Special Connittee On 'mechanism And Chemotherapy For Adult Refractory Leukemia&apo

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis
Acquired hemophilia A with sigmoid colon cancer : successful treatment with rituximab followed by sigmoidectomy
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma : β2-microglobulin associated with time to progression
Dose Modification of Imatinib by Monitoring the Level of BCR-ABL Transcript in Chronic Myelogenous Leukemia
Increased Expression of Insulin-Like Growth Factor I is Associated with Ara-C Resistance in Leukemia
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Case-control study of leukemia and diagnostic radiation exposure
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice
Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients
Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

もっと見る

スポンサーリンク